ReviewBMC anesthesiology2024
Remimazolam anaphylaxis in a patient not allergic to brotizolam: a case report and literature review.
Review in BMC anesthesiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Remimazolam Reduces the Cough Reflexes in Elderly Patients Undergoing Fiberoptic Bronchoscopy Under Remifentanil/Cipepofol-Based Anaesthesia: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Possible bronchospasm relief following flumazenil administration in a remimazolam-induced Grade III hypersensitivity reaction: a case report.Journal of medical case reports · 2026Article
- Remimazolam-Induced Anaphylaxis After Spinal Anesthesia: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Local Urticarial Reaction Above the Site of an Intravenous Cannula: Possible Allergy to Remimazolam in a Fourteen-Year-Old Adolescent.Journal of medical cases · 2026Article
- Hypersensitivity Reactions to Benzodiazepines Used for Perioperative Premedication: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review of clinical advances in the procedural sedation application of remimazolam.Frontiers in pharmacology · 2026Review
- Remimazolam in anesthesia and sedation: A narrative review.Journal of anesthesia and translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemimazolam is a recently developed, ultrashort-acting benzodiazepine that is used as a general anesthetic. Some cases of remimazolam anaphylaxis have been reported, but its characteristics are not fully understood. We present an interesting case report and review of the literature to better understand remimazolam anaphylaxis. CASE PRESENTATION: A 75-year-old man scheduled for robot-assisted gastrectomy was administered remimazolam for the induction of general anesthesia. After intubation, low end-expiratory CO
conclusionsRemimazolam is an ultrashort-acting sedative; however, it can cause life-threatening anaphylaxis. In addition, its cross-reactivity with other benzodiazepines is not fully understood. To increase the safety of this drug, further research and more experience in its use are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.